Test Price
2,800 AED✅ Home Collection Available
PEX11B Gene Peroxisome Biogenesis Disorder 14B Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل جين PEX11B لاضطراب تكون البيروكسيسوم النوع 14B في الإمارات | 2,800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & Patient Commitment | ملخص تنفيذي والتزام المريض
This test delivers 99.9% diagnostic sensitivity for PEX11B-related peroxisome biogenesis disorders via ISO‑certified Next‑Generation Sequencing. Our clinically supervised service includes pre‑test genetic counselling, hospital‑grade home collection (8 AM–11 PM), rapid 3‑4‑week turnaround, and direct insurance verification—all compliant with UAE Federal Decree‑Law No. 41 of 2024 and DHA guidelines.
يقدم هذا التحليل حساسية تشخيصية بنسبة 99.9% لاضطرابات تكون البيروكسيسوم المرتبطة بجين PEX11B عبر تقنية التسلسل الجيني من الجيل التالي المعتمدة من ISO، ويتضمن استشارة وراثية قبل الفحص، وسحب عينات منزلي بمستوى المستشفيات (من الثامنة صباحًا حتى الحادية عشرة مساءً)، وإصدار النتائج خلال 3–4 أسابيع، والتحقق المباشر من التأمين الصحي، مع الامتثال الكامل للمرسوم بقانون اتحادي رقم 41 لسنة 2024 وتوجيهات هيئة الصحة بدبي.
1. What Is the PEX11B Gene NGS Test?
The PEX11B Gene Peroxisome Biogenesis Disorder 14B Genetic Test screens the entire coding region of the PEX11B gene using Next‑Generation Sequencing to detect pathogenic variants responsible for severe peroxisomal biogenesis disorders, including Zellweger spectrum phenotypes and neonatal metabolic crises. This DHA‑recognised assay identifies single‑nucleotide variants, small indels, and copy‑number changes with 99.9% analytical accuracy, enabling early neurological intervention and family planning in the UAE.
| Feature | Our PEX11B NGS Test (ISO 9001:2015) | Closest Alternative (Standard Panel) |
|---|---|---|
| Methodology | Full gene sequencing (NGS) with CNV analysis – LC‑MS/MS‑validated | Targeted mutation panel, may miss rare variants |
| Coverage | > 99% of coding exons ±10 bp splice sites; 100× mean depth | ~85% of known mutations; limited intronic regions |
| Turnaround Time | 3–4 weeks (fast‑track available) | 4–6 weeks |
| Data Privacy | UAE PDPL‑compliant; data stored in Dubai onshore servers | Not always locally compliant |
* When clinically indicated, our rapid protocol can deliver results in 10–14 days for urgent neonatal cases. Contact our genetic counselling team for priority activation.
2. Physician Insight & Clinical Safety Protocol
A Clinician‑to‑Parent Note
“As a DHA‑licensed paediatric neurologist, I recognise the profound anxiety families experience when a peroxisomal disorder is suspected. The PEX11B NGS test is a critical step toward a definitive diagnosis, but a negative result does not exclude all peroxisomal biogenesis defects—clinical correlation, biochemical markers (VLCFA), and repeat imaging remain essential. Please do not alter any prescribed medication or feeding protocol without consulting your treating physician.”
— Dr. Prabhakar Reddy, DHA License No. 61713011
⚠️ Medication Warning
Do not discontinue prescribed medication or supplements based on genetic test results alone. Always consult your supervising physician before making any changes to treatment.
- Patients currently on anti‑epileptic drugs or ketogenic diet must continue therapy under strict neurological supervision.
- In case of new‑onset seizures, lethargy, or metabolic decompensation, present immediately to the nearest Emergency Department.
- Exclusion criteria: infants < 36 weeks corrected gestational age (for home collection) or advanced critical illness requiring inpatient care.
3. Patient FAQ & Clinical Guidance
Is the PEX11B NGS test necessary if my child’s MRI shows slowed myelination?
This directly sequences the PEX11B gene to confirm peroxisome biogenesis disorder 14B, providing a molecular explanation for hypomyelination patterns seen on MRI. Because peroxisomal disorders often present with non‑specific white‑matter changes, a negative NGS result may still warrant comprehensive peroxisomal profiling (VLCFA and plasmalogen analysis) and repeat genetic testing if clinical suspicion remains high.
هل يمكن إجراء تحليل جين PEX11B قبل الحمل للكشف عن الحامل للمرض الوراثي؟
نعم، يمكن إجراء التسلسل الكامل لجين PEX11B للكشف عن الحاملين للمرض في مرحلة ما قبل الحمل، حيث يوفر هذا التحليل دقة تتجاوز 99% لاكتشاف الطفرات الممرضة، مما يساعد العائلات ذات التاريخ المرضي في الإمارات على اتخاذ قرارات إنجابية مستنيرة ضمن إطار الاستشارة الوراثية المعتمدة من هيئة الصحة بدبي وقانون الجينوم البشري الاتحادي.
(English summary: Carrier screening before pregnancy is possible and delivers >99% accuracy for pathogenic variants, aiding family planning under DHA‑approved genetic counselling.)
How can I trust the privacy of my child’s genetic data in the UAE?
All PEX11B genetic data is processed onshore in ISO 9001:2015‑certified facilities compliant with UAE PDPL (Federal Decree‑Law No. 45 of 2021) and the genetic privacy provisions of Federal Decree‑Law No. 41 of 2024 (Art. 87). Our laboratory does not share identifiable genetic information with third parties, and minor age consent protocols strictly follow Cabinet Decision No. (2) of 2026.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians